Soluble guanylate cyclase (sGC) is an important enzyme in corpus cavernosum smooth muscle cells as it is one of the regulators of the synthesis of cGMP. The efficacy of sildenafil (Viagra TM ) in the treatment of male erectile dysfunction indicates the importance of the cGMP system in the erectile response as the increased levels of cGMP induce relaxation of the corpus cavernosum. sGC is physiologically activated by nitric oxide (NO) during sexual stimulation, and its activity can be pharmacologically enhanced by several NO-donors. Agents like YC-1 can also activate sGC after binding to a novel allosteric site in the enzyme, a site different from the NO binding site. YC-1 can relax rabbit cavernosal tissue and it facilitates penile erection in vivo. This review summarizes the enzymology, biochemistry and pharmacology of this novel allosteric site and its relevance for the regulation of penile function. This type of sGC activators represent a new class of compounds with a different pharmacological profile in comparison to the classical NO-donors and they could be beneficial for the treatment of male erectile dysfunction.
Introduction
The treatment of male erectile dysfunction (MED) has evolved during the last decade from surgical options or intracavernosal -intraurethral injections to the recent development of oral therapies such as sildenafil (Viagra TM ). The efficacy of IC351 and vardenafil in clinical trials has strengthened the notion that blockade of phosphodiesterase 5 (PDE5) in the corpus cavernosum is a successful approach. The efficacy of apomorphine in a sublingual formulation in phase III trials and its recent approval by the CPMP in Europe also indicate that MED can be treated by agents that act at the neuronal level via central mechanisms. Several other targets may also be useful for the treatment of MED, and the biochemical and neurological bases to facilitate the erectile response has recently been reviewed. 1 Penile erection is the end result of corpus cavernosum trabecular smooth muscle relaxation that was initiated by nitric oxide (NO). These processes are mediated in part by nerves expressing nitric oxide synthase I (neural-NOS), as sexual stimulation results in the peripheral release of NO. This neurally-derived NO mediates the initial dilation of the helicine resistance arterioles as well as the trabecular smooth muscle, resulting in an increase of arterial blood flow which further activates the endothelial NOS (type II) releasing more NO down into the smooth muscle layers. NO activates soluble guanylate cyclase (sGC) in the corpus cavernosum smooth muscle. sGC is responsible for the enzymatic conversion of GTP to cyclic GMP (cGMP), and the increase of cGMP mediates relaxation of cavernosal smooth muscle leading to penile erection.
The discovery that NO-sGC-cGMP system is one of the major effectors in penile smooth muscle relaxation and erectile function has led to the development of two classes of agents: (a) agents that inhibit cGMP degradation like the PDE inhibitors; (b) agents that elevate cGMP levels through potentiation of cGMP synthesis. Sildenafil increases cGMP levels by inhibiting PDE5, the enzyme that degrades cGMP. NO and NO-donors are well-known sGC activators and the examples of drugs that work as NO-donors include nitroglycerine, minoxidil, sodium nitroprusside, and S-nitrosylated derivatives of other drugs. So far, among the various sGC activators, only NO-donors have been considered as drug candidates for MED.
A novel type of sGC activators is represented by YC-1 ( Figure 1 ). This agent is not an NO-donor, but causes activation of sGC especially in the presence of NO. The binding site for NO was the only site reported to modulate sGC activity ( Figure 2) . However, the finding that YC-1 activates sGC by binding to an allosteric site on the enzyme opened the possibility to discover a new class of compounds with a different pharmacological profile in comparison to the NO-donors.
In this review we summarize the biochemical and pharmacological data that indicate that activation of sGC via an allosteric site in the enzyme can lead to facilitation of penile responses in animals. The regulation of sGC activity by this type of sGC activators may represent a novel approach to regulate penile erection.
Cloning and expression of soluble guanylate cyclase subunits
The guanylate cyclases [GTP pyrophosphatase-lyase (cyclizing); EC 4.6.1.2] are a family of enzymes that catalyze the conversion of GTP to cGMP. They are expressed in particulate and soluble forms, and while they share similar structural characteristics, they differ in their mechanisms of physiological regulations. Most importantly, sGC contains a heme group and binds NO that activates the enzyme, while particulate GC is stimulated by natriuretic peptides.
sGC has been purified to apparent homogeneity and it exists as a heterodimer (Figure 2 ). The larger molecular weight subunit is designated a (82 kDa) and the smaller subunit, b (70 kDa). The first sGC cDNA isolated was for the b subunit from the rat. 2 However, no enzyme activity was observed when the b subunit cDNA was transfected into L cells, an established cell line derived from mouse connective tissue. 3 A novel sGC subunit was isolated from rat kidney using the catalytic domain sequence of sGC by PCR and subsequently designated the b 2 subunit. 4 This subunit is preferentially expressed in rat kidney and liver. Recently, co-expression of the rat b 2 subunit revealed that a 1 b 2 heterodimers are inactive and that this subunit may be an inhibitor of the a 1 b 1 subunit. 5 Harteneck et al isolated a cDNA coding for a second novel subunit of sGC from human fetal brain and designated as a 2 subunit. 6 Co-expression of the a 2 subunit with the b 1 subunit showed active sGC activity indistinguishable from a 1 b 1 heterodimer, demonstrating the interchangeability of the subunit isoforms.
Giuili et al have also isolated cDNAs corresponding to both a and b subunits of sGC from human brain, and designated them a 3 and b 3 . 7 However, Zabel et al re-sequenced these cDNA and found that they were in fact authentic human a 1 and b 1 . 8 To date, only a 1 , a 2 , b 1 and b 2 have been cloned and sequenced.
Although two isoforms for each subunit have been cloned, a 1 and b 1 are the main isoforms expressed in most of the mammalian tissues including brain, lung and liver. 3 Behrends et al characterized the sGC in human corpus cavernosum by revserse transcription-polymerase chain reaction (RT-PCR), and found that a 1 and b 1 are also the main isoforms expressed in human corpus cavernosum. 9 Studies conducted in our laboratory also confirmed the expression of a 1 and b 1 subunits as the main isoforms in human corpus cavernosum. 10 Enzymology of soluble guanylate cyclase sGC is a heterodimeric protein consisting of a and b subunits. 11 The a and b subunits contain a Cterminal homologous domain to adenylate cyclase that constitutes the catalytic center. 12 The N-terminal domains of both subunits are essential for the stimulation of the enzyme by NO, although heme Activators of soluble guanylate cyclase JD Brioni et al binding occurs in the b subunit. sGC contains one mole prosthetic heme per heterodimer attached to histidine 105 of the b subunit, which is required for the activation of the enzyme by NO. 13 Several agents that modulate the activity of sGC have been identified (Figure 1 ). ODQ, a quinoxaline derivative, is a potent inhibitor of sGC in brain slices (IC 50 ¼ 20 nM), providing an important tool to identify cGMP-dependent signaling. ODQ binds to sGC in an NO-competitive manner and inhibits NOstimulated activity, leaving basal activity unchanged. However, the inhibitory effect of ODQ is due to oxidation of the heme ion, indicating that ODQ may affect various heme-containing enzyme activities. 14 The ODQ analog, NS 2028, was described as another potent inhibitor of sGC (IC 50 ¼ 30 nM). 15 Methylene blue 16 and LY-83583 17 were reported as inhibitors of sGC, but they are less potent than ODQ and NS 2028. Furthermore, they inhibit not only sGC activity but they affect the biological activity of NO synthase and glucose transporters. 18, 19 Isoliquiritigenin, isolated from Dalbergia odorifera T, was originally identified as a vasorelaxant and later was found to activate sGC. 20 It induces relaxation of rat aortic rings and increases intracellular Ca 2þ in heart muscle, but the effects of isoliquiritigenin may be due to inhibition of PDE activity rather than activation of sGC. 21, 22 YC-1, on the other hand, was initially identified as an inhibitor of platelet aggregation. 23 Soon after the discovery of the pharmacological effect of YC-1 on platelets, YC-1 was found to be a modulator of sGC activity. 24 YC-1 stimulates basal sGC and it is not blocked by NO scavengers indicating that the effect of YC-1 is NO-independent. Interestingly, YC-1 highly potentiates the stimulatory effect of submaximally activating NO. In the presence of YC-1, the NO concentration -response curve is shifted to the left, indicating that YC-1 sensitized sGC towards NO.
Biochemistry of the NO-cGMP system: allosteric sites in sGC
The structure of sGC yields clues as to its mechanism of action. The two subunits described above share extensive homology in the C-terminal region to the active site of adenylate cyclase. 12 Membrane bound adenylate cyclase is activated by either the binding of specific G-proteins or by the terpenoid forskolin. sGC is activated by NO via a heme prosthetic group bound in the fifth position to histidine 105 of the b 1 subunit (Figure 3 ). This process is thought to occur by the rapid binding (t1 2 ¼ 0.21 ms) of NO to the sixth position in the ferrous heme yielding a six liganded complex. 25 This intermediate then undergoes a relatively slow transition (t1 2 ¼ 630 ms) breaking the protein histidine bond, oxidizing the iron to the ferric state and leading to activated sGC. In this activated state, both the K m for GTP decreases and the V max for cGMP formation increases. 26 Since the X-ray crystallographic structure of sGC has yet to be reported, it is unclear exactly what transpires to activate sGC. Sedimentation or CD-ORD spectral analyses do not detect gross changes in conformational structure.
With analogy to forskolin-activated adenylate cyclase, there could be a subtle conformational change, favoring a more efficient GTP cyclizing activity at the active site. sGC is unusual as a hemoprotein in that the protein-heme bond breaks .
Activators of soluble guanylate cyclase JD Brioni et al as part of activation, a process not seen in hemoglobin, P450s, oxidases or the cytochromes. 12 Once activated, thiols such as glutathione can reduce the ferric-NO heme complex to ferrous heme-histidine 105 bond once again. 27 The sGC inhibitor ODQ works by oxidizing the ferrous heme in the first complex to a five liganded ferric intermediate and this prevents both binding and activation by NO. Allosteric sites are defined as topographically distinct sites from the catalytic domain on an enzyme or protein. 28 An allosteric effector is defined as a substance that changes the kinetic properties of an enzyme but structurally it does not resemble the substrate, and allosteric effects are thought to occur through conformational changes in the enzyme upon binding of the molecules. 29 For sGC, allosteric modulators would be any molecules that do not resemble GTP. Examples would include activators like NO, NO-donors, YC-1 and inhibitors such as ODQ. In biological systems, the most common allosteric effect is feedback or product-induced inhibition characterized in many biosynthetic pathways (for example, gluconeogenesis, tricarboxcylic acid cycle, amino acid synthetic pathway). However, allosteric effects can include activation rather than inhibition. In these cases, changes in the kinetic behavior of the enzyme include decreases in the K m (increased affinity for substrate requiring less for activity) and=or increases in V max , the maximum velocity of the enzyme. The latter can be thought of as making the enzyme more efficient so that more product per unit time is produced. In the case of sGC, both NO, NO-donors (sodium nitroprusside) and YC-1 act as allosteric activators by increasing both K m and V max (see later).
While NO mediates its physiological actions via binding to an allosteric site in sGC (the heme), YC-1 binds to a second allosteric site in the enzyme. 30 Although YC-1 has been described in the literature as an NO-independent activator, this issue warrants further clarification. YC-1 binds to a 'heme-independent site' but its effects on enzyme activity can be defined as 'NO-independent' (effect on basal activity in the absence of NO) and 'NO-dependent' (effect on enzyme activity in the presence of NO).
YC-1 binds to sGC at a different site from the heme and this is evidenced by studies in which YC-1 can act as an allosteric activator in the absence of NO and lead to even more activation in the presence of NO, decreasing the K m for GTP and increasing the V max of cGMP formation. 26 This site has recently been mapped using a photoaffinity labeling technique to a subunit cysteines 238 and 243 of human sGC. 31 This report is not in agreement with earlier work that suggested that cysteine 541 of the b subunit was important for the YC-1 interaction and that YC-1 binds to the heme-binding domain. 32 This may reflect the nature of the conformational change as well as the initial binding of YC-1. For sGC to possess two different allosteric sites is fortuitous therapeutically. Ideally one would wish to develop an sGC activator that binds to the allosteric nonheme site that in itself has little effect on increasing the basal activity, but that in the presence of NO, this activator would greatly amplify the effects of NO.
The endogenous ligand that binds to the YC-1 site as well as the potential role of this site on the selfregulation of sGC activity is unknown at the present time, but it may represent an attractive area of scientific inquiry in the future. These multiple sites for allosteric regulation may provide sGC with a sensitive and versatile way to respond to intracellular changes in the cell leading to relaxation or contractile events.
In vitro and in vivo pharmacology
sGC is expressed in most cells of the cardiovascular system and in many other cell types. 33 The levels of sGC mRNA and protein often change in response to different physiological conditions and development stages. By formation of cGMP as a second messenger, sGC plays an important role in different physiological processes and is considered the key enzyme mediating vascular relaxation induced by NO and NO-releasing agents. The ability of NO to relax smooth muscle has been described in multiple models and muscle types, including vascular smooth muscle, 34 tracheal smooth muscle, 35 corpus cavernosum smooth muscle, 36, 37 and myometrium. 38 Carbon monoxide (CO), another physiological activator of sGC, is also capable of binding to the heme group of sGC and converts GTP to cGMP after activation. However, NO is more potent activator of sGC than CO, and the purified enzyme is activated 100 to 200-fold by NO, but only about 4-fold by CO. 39 In recent years, the introduction of the potent and specific sGC inhibitor ODQ 40 has helped to identify more precisely the sGC-mediated effects in various tissues. Using rat artery rings, Homer et al, demonstrated that ODQ (3 mM) completely abolished the relaxant responses to glyceryl trinitrate, isosorbide dinitrate and sodium nitroprusside. 41 This inhibitor has been extensively used in vitro to examine the specificity of sGC activation and it was shown that the sensitivity of ODQ-mediated inhibition of vascular relaxation appeared to be different among NO donors. 42 The vasorelaxation can be induced through exclusive activation of the heme site of sGC for the NO donors such as sodium nitroprusside. On the other hand, some NO donors such as Snitrosothiols may also activate cellular vasodilating mechanisms through interaction with sulfhydryl site(s) of sGC and such biochemical mechanism(s) may not be available to other NO donors that only bind to conventional NO binding site. 42 Activators of soluble guanylate cyclase JD Brioni et al YC-1 is a direct activator of sGC through a pathway that does not involve the interaction with the heme moiety and causes a pronounced activation of the enzyme in the presence of NO. 30 YC-1 induced a concentration-dependent relaxation (EC 50 ¼ 2.9 mM) in rat aortic rings precontracted with phenylephrine, and the effects of YC-1 were blocked by ODQ, whereas YC-1 (30 mM) exhibited no effects on the contractile force of ventricular muscle strips. 43 cGMP-increasing effects of YC-1 have been reported in vascular smooth muscle cells and an increase in responsiveness toward NO has been shown to be substantially higher in intact cell than in cell-free purified enzyme system. 24 Stimulation of the vascular endothelial cells with YC-1 increased cGMP accumulation up to 100-fold, an effect that was further potentiated by NO. 44 The maximal effect of YC-1 was diminished in the presence of NOS inhibitors. As YC-1 does not activate endothelial NO synthase, the pronounced effect of YC-1 on cGMP accumulation is apparently caused by the synergistic activation of sGC by YC-1 and basal endogenous NO released from the endothelial cells. Using an aortic rings organ bath preparation, O'Reilly et al also demonstrated that a non-vasorelaxant concentration of YC-1 enhanced the ability of organic nitrates to relax vascular smooth muscle and elevate intravascular cGMP levels. 45 Penile erection involves relaxation of corporal smooth muscle during sexual stimulation. 46 During the last decade, the application of in vitro model systems of isolated corpus cavernosal tissue has significantly enhanced our understanding of the biochemical mechanisms of potentially therapeutic drugs for the treatment of MED. 1 Primary cultures of corpus cavernosal cells from human or animals have provided useful insights into factors that can modulate the intracellular components important to the corporal activity. The corpus cavernosal smooth muscle in organ bath preparations has also been widely used to assess the pharmacological effects of the contractile or relaxation agents. Submicromolar concentrations of NO have been shown to cause significant changes in smooth muscle tone and increases in cGMP levels in the corpus cavernosum cells, and a positive correlation was found between the magnitudes of relaxation and cGMP formation. 37 Recently, Liu et al, reported that YC-1 enhanced the relaxing effects of sodium nitroprusside in rabbit corpus cavernosum strips in a concentration-dependent manner and demonstrated that relaxation is mediated via increasing intracellular cGMP levels. 47 Pharmacological studies in vivo support these in vitro findings. The systemic administration of YC-1 significantly prolonged tail bleeding in mice at 3 -30 mg=kg doses, consistent with the inhibition of platelet aggregation exhibited by YC-1 in vitro. 48, 49 Systemic injections of YC-1 facilitate penile erections in rats, indicating that the activation of sGC via this allosteric site in the enzyme can lead to penile erection in mammals. 50, 51 YC-1 in combination with SNP caused a strong decrease in mean arterial pressure in hypertensive as well as normotensive rats after intravenous injections. 52 The hypotensive effect may be related to the activation of sGC in vascular tissue, and in view of the cardiovascular liabilities of sildenafil in MED patients, the cardiovascular effects of YC-1 deserve further investigation. Although YC-1 has already been proposed for the treatment of cardiovascular and thrombotic disorders, YC-1 as well as activators of sGC may also be beneficial for the treatment of MED.
Male erectile dysfunction: physiology and pathophysiology
The tone of the corpus cavernosum smooth muscle is controlled at the level of the peripheral as well as the central nervous system (CNS). Within the CNS, many different neurotransmitters (such as dopamine and oxytocin) as well as different brain regions (for example, cortical association centers, medial preoptic area of the hypothalamus) are involved in penile erection. The reader is referred to more detailed reviews on the subject. 1, 46 Ultimately, corpus cavernosum smooth muscle tone regulates penile flaccidity and erection. During flaccidity, the helicine resistance arterioles are constricted, principally through a-adrenergic mechanisms although endothelin and constrictor prostanoids may play a role. Penile erection is the end result of smooth muscle relaxation and this relaxation can be initiated by sensory stimulation that activates CNS pathways. NO from NANC nerves mediates the dilation of the helicine arterioles as well as the trabecular smooth muscle via activation of sGC. NO diffuses into the smooth muscle also activating sGC and further enhancing relaxation. As the corpus cavernosum sinuses relax and fill with blood, intracavernosal pressure and volume increases and veno-occlusion ensues.
MED is defined as the consistent inability to attain or maintain penile erection satisfactory for intercourse. It has become recognized that 75% of this condition has organic origins. Pathophysiology of MED can be thought to have a structural component as well as a metabolic component. 53 The penis is comprised of soft tissue and functions as a blood-filled capacitor of sufficient rigidity during erection for vaginal penetration. The corpora cavernosa, that are integral to this function are composed of a specialized vascular bed that has a high content of connective tissue (48 -55%). The corpus cavernosum smooth muscle cells also synthesize connective tissue that contributes to the structural integrity of the corpora, and a functional corpus cavernosum smooth muscle=connective Activators of soluble guanylate cyclase JD Brioni et al tissue ratio is necessary for veno-occlusion. 53 Thus, regardless of the amount of corpus cavernosum smooth muscle relaxation, veno-occlusion cannot occur in some patients due to higher content of connective tissue and an inability to occlude the draining venules. One area of active research in MED is to identify vasoactive factors, cytokines, autacoids and=or neurotransmitters which may play a role in maintaining the connective tissue=smooth muscle balance. A metabolic imbalance between contractile and relaxatory factors in the corpus cavernosum can also contribute to the pathophysiology of MED (dysfunctional antagonism). 54 Under normal physiologic conditions in the penis, contractile factors (norepinephrine, endothelin and contractile prostanoids) are in balance with relaxatory factors (NO, VIP) such that when the contraction of the corpus cavernosum diminishes and relaxatory factors are present, erection ensues. In the case of dysfunctional antagonism, contractile factors predominate, are over-expressed or relaxatory factors are inhibited; such that the trabecular smooth muscle remains contracted and the penis, flaccid. This is particularly important with sGC. In certain disease states such as diabetes or in radical prostatectomy patients post surgery that experience nerve damage, NO responses may be impaired. It has been demonstrated in diabetic models that sGC activity is not compromised, while NO synthesis is diminished. 55 This would suggest that in certain disease states where NO is compromised that an sGC activator may be an effective therapy for MED.
Conclusions
sGC is an important enzyme in corpus cavernosum smooth muscle cells as it regulates the synthesis of cGMP. A novel type of GCA is represented by YC-1 as this agent is not an NO-donor, but causes activation of sGC. YC-1 activates sGC by binding to a second allosteric site on the enzyme, and in vivo studies have shown that it facilitates penile erections in rats. YC-1 binds to a 'heme-independent site' but its enzymatic effects are 'NO-independent' as well as 'NO-dependent' as YC-1 leads to even more activation in the presence of NO than in the absence of NO. Agents such as YC-1 that activate sGC enhancing the activity of NO in the corpus cavernosum may represent a novel approach for the treatment of erectile dysfunction. These differ from PDE5 inhibitors in that they amplify the existing amount of NO rather than blocking degradation of cGMP produced by endogenous NO. This type of sGC activators represent a new class of compounds with a different pharmacological profile in comparison to the classical NO-donors and they may be beneficial for the treatment of MED.
